• Vaccine Name: ALVAC-WNV-prM/E
• Target Pathogen: West Nile virus
• Target Disease: West Nile fever
• Vaccine Ontology ID: VO_0004731
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: Baboon
• Vector:
  • Vector name:
  • VO vector ID: VO_0001043
• Preparation: Three commercially available equine WNV vaccines in horses: (i) an inactivated WNV vaccine (K-WN), (ii) a modified-live vaccine (CP-WN) containing the WNV prM and E proteins expressed by a canarypox vector, (iii) a live-chimera vaccine (WN-FV) containing WNV prM and E proteins expressed in a YF17D vector (Seino et al., 2007).
• Immunization Route: Intramuscular injection (i.m.)

Horse Response

• Vaccination Protocol: Twenty-four healthy, WNV-seronegative horses of varying ages and genders were placed, in random and blind manner, into three trial groups consisting of eight horses each; two horses in each group received one of the three vaccines being tested (Seino et al., 2007).
• Vaccine Immune Response Type: VO_0003057
• Challenge Protocol: The horses were challenged with designated WNV NY99 (Seino et al., 2007).
• Efficacy: Challenge in horses at between 28 days postvaccination with the chimera vaccine and 56 days postvaccination with the commercial inactivated or modified-live vaccine resulted in 100% survivorship (protection from the onset of WNV encephalitis and viremia). Horses vaccinated with the live-chimera vaccine showed significantly fewer clinical signs than did the control horses and the horses vaccinated with inactivated vaccine (Seino et al., 2007).